Literature DB >> 10094436

Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus.

F M Müller1, A H Groll, T J Walsh.   

Abstract

UNLABELLED: The prolonged survival of profoundly immunocompromised patients has revealed mucosal and invasive fungal infections to be major causes of morbidity and mortality in advanced HIV disease in children of all age groups. Antifungal resistance has become a clinically relevant problem. Paediatricians caring for HIV-infected children need to be aware of these increasingly frequent and often life-threatening infectious complications. This article reviews what is currently known about epidemiology, clinical presentation, diagnosis and treatment of mucosal and invasive fungal infections in children and adolescents with HIV disease. Candida spp. have become a leading bloodstream isolate in hospitalised patients; mucosal candidiasis is the most prevalent opportunistic infection in HIV-infected patients, and in both invasive and superficial infections, non Candida albicans spp. are on the increase. Invasive pulmonary aspergillosis has surfaced as an HIV-associated complication and previously uncommon fungi are more frequently encountered. HIV-infected individuals are particularly susceptible to Peumocystis carinii, Cryptococcus neoformans and infections by endemic fungi, such as Histoplasma capsulatum, Coccidioides immitis, Penicillium marneffei, and others. Newer immunological and molecular-based methods provide early and rapid diagnosis and monitoring. Potent and broad-spectrum third generation triazoles and novel fungicidal lipopeptides of the echinocandin class of antifungal antibiotics have entered clinical trials. Immunmodulation by recombinant cytokines and antifungal vaccines are very actively pursued inroads to adjunctive and preventive immunotherapy.
CONCLUSION: Mucosal and invasive fungal infections will remain important complications in HIV-infected children of all age groups. Interventional studies and well documented case series are needed to improve the molecular diagnosis, treatment and prevention of invasive fungal infections in the paediatric HIV-infected population.

Entities:  

Mesh:

Year:  1999        PMID: 10094436     DOI: 10.1007/s004310051047

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  6 in total

Review 1.  Milestones in Candida albicans gene manipulation.

Authors:  Dhanushki P Samaranayake; Steven D Hanes
Journal:  Fungal Genet Biol       Date:  2011-04-14       Impact factor: 3.495

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

Review 5.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Role of Ess1 in growth, morphogenetic switching, and RNA polymerase II transcription in Candida albicans.

Authors:  Dhanushki Samaranayake; David Atencio; Randall Morse; Joseph T Wade; Vishnu Chaturvedi; Steven D Hanes
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.